Trillium Asset Management LLC Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Trillium Asset Management LLC boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.1% in the 2nd quarter, Holdings Channel reports. The firm owned 61,474 shares of the pharmaceutical company’s stock after buying an additional 5,658 shares during the quarter. Trillium Asset Management LLC’s holdings in Vertex Pharmaceuticals were worth $27,370,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of VRTX. Brighton Jones LLC lifted its holdings in Vertex Pharmaceuticals by 15.0% during the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after buying an additional 579 shares in the last quarter. World Investment Advisors bought a new stake in Vertex Pharmaceuticals during the 1st quarter valued at $424,000. Concurrent Investment Advisors LLC raised its position in Vertex Pharmaceuticals by 55.1% during the 1st quarter. Concurrent Investment Advisors LLC now owns 3,213 shares of the pharmaceutical company’s stock valued at $1,558,000 after purchasing an additional 1,141 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Vertex Pharmaceuticals by 11.3% in the first quarter. Envestnet Asset Management Inc. now owns 470,328 shares of the pharmaceutical company’s stock valued at $228,024,000 after acquiring an additional 47,630 shares in the last quarter. Finally, Raleigh Capital Management Inc. raised its holdings in shares of Vertex Pharmaceuticals by 100.4% in the first quarter. Raleigh Capital Management Inc. now owns 473 shares of the pharmaceutical company’s stock valued at $229,000 after acquiring an additional 237 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on VRTX shares. Barclays boosted their price objective on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Evercore ISI reduced their target price on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a report on Thursday, September 11th. Morgan Stanley reduced their price objective on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Canaccord Genuity Group reduced their price target on Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating on the stock in a research report on Wednesday, August 6th. Finally, HC Wainwright reduced their price target on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $489.45.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $421.67 on Wednesday. The business’s 50-day moving average is $403.14 and its two-hundred day moving average is $430.65. The company has a market capitalization of $108.11 billion, a P/E ratio of 30.14 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, topping the consensus estimate of $4.58 by $0.22. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.Vertex Pharmaceuticals’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period last year, the company earned $4.38 earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.